Vitali Y. Alexeev, PhD
Bluemle Life Sciences Building, Room 430
Philadelphia, PA 19107
Most Recent Peer-reviewed Publications
- Human adipose-derived stem cell transplantation as a potential therapy for collagen VI-related congenital muscular dystrophy
- Chemokine-enhanced DNA vaccination in cancer immunotherapy
- Immunotargeting and eradication of orthotopic melanoma using a chemokine-enhanced DNA vaccine
- Analysis of chemotactic molecules in bone marrow-derived mesenchymal stem cells and the skin: Ccl27-Ccr10 axis as a basis for targeting to cutaneous tissues
- Interleukin 10 in the tumor microenvironment: A target for anticancer immunotherapy
PhD Cell Biology, Institute of Cytology, Russian Academy of Science - 1996
Research and Clinical Interests
My current, vaccine-related research is focused on the analysis of the chemokines’ activity during immune response induction and on the development of chemokine-mediated strategies of immune response stimulation. My laboratory recently assessed the applicability of the secondary lymphoid chemokine, CCL21 for stimulation of melanoma-specific immune responses (Novak L, Igoucheva O, Cho S, Alexeev V. Characterization of the CCL21-mediated melanoma-specific immune responses and in situ melanoma eradication. Molecular cancer therapeutics 2007;6 (6):1755-64). My laboratory is currently working on the development of practically applicable approaches for the treatment of cutaneous melanomas using chemokines in conjunction with (i) melanoma DNA vaccines and (ii) suicidal gene therapy.
In addition, I am collaborating with Dr. T. Sato (Department of Medical Oncology) on the research project related to the development on novel approaches of tumor-specific immune response induction using IL-10 antagonism.
The membership in the JVC will allow me to closely interact with researchers and clinicians, who are involved in the research, testing and application of anti-cancer vaccines, which potentially may lead to the establishment of new collaboration project. I believe, these interactions will also allow me to extend my knowledge in cancer vaccines and understanding of clinical needs.